Local injection plus systemic therapy for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a local injection into the lung tumor combined with a systemic therapy (Endostar) for people with advanced non-small cell lung cancer who have already tried a standard treatment. The goal is to see if this combination can help shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have advanced or metastatic non-small cell lung cancer (stage IIIB, IIIC, or IV) without certain gene mutations (like EGFR or ALK)
- You have tried at least one standard treatment that didn't work or stopped working
- You have at least one tumor that can be measured on a scan, and it hasn't been treated with radiation
- A scan shows that at least one lobe of your lung has collapsed (atelectasis)
- You are in good enough health to be up and about (ECOG 0 or 1) and are expected to live at least 3 more months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This trial tests a new immunotherapy (Envafolimab) combined with standard chemotherapy before and after surgery for stage III non-small cell lung cancer that can be removed. The goal is to see if adding Envafolimab helps shrink the tumor and improve outcomes compared to chemotherapy alone.
This study tests a combination of two targeted drugs (envafolimab and disitamab vedotin) plus chemotherapy (carboplatin) given before surgery for lung cancer that has a HER2 mutation. The goal is to see if this can shrink the tumor and improve outcomes.
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.